company background image
IVA

Inventiva ENXTPA:IVA Stock Report

Last Price

€8.83

Market Cap

€360.8m

7D

1.0%

1Y

-24.0%

Updated

23 May, 2022

Data

Company Financials +
IVA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

IVA Stock Overview

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

Inventiva Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Inventiva
Historical stock prices
Current Share Price€8.83
52 Week High€13.18
52 Week Low€8.30
Beta1.0
1 Month Change-10.08%
3 Month Change-18.24%
1 Year Change-24.01%
3 Year Change267.92%
5 Year Change16.95%
Change since IPO2.91%

Recent News & Updates

Shareholder Returns

IVAFR BiotechsFR Market
7D1.0%2.3%-1.3%
1Y-24.0%-39.0%-5.4%

Return vs Industry: IVA exceeded the French Biotechs industry which returned -39% over the past year.

Return vs Market: IVA underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is IVA's price volatile compared to industry and market?
IVA volatility
IVA Average Weekly Movement3.9%
Biotechs Industry Average Movement8.9%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.5%
10% least volatile stocks in FR Market3.6%

Stable Share Price: IVA is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: IVA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011103Frederic Crenhttps://www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease.

Inventiva Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
IVA fundamental statistics
Market Cap€360.79m
Earnings (TTM)-€49.63m
Revenue (TTM)€8.50m

42.4x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IVA income statement (TTM)
Revenue€8.50m
Cost of Revenue€1.02m
Gross Profit€7.48m
Other Expenses€57.12m
Earnings-€49.63m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.21
Gross Margin88.04%
Net Profit Margin-583.87%
Debt/Equity Ratio11.2%

How did IVA perform over the long term?

See historical performance and comparison

Valuation

Is Inventiva undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


4.06x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IVA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IVA's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IVA is overvalued based on its PB Ratio (4.1x) compared to the FR Biotechs industry average (2.6x).


Future Growth

How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IVA's revenue (63.9% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: IVA's revenue (63.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Inventiva performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-22.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IVA is currently unprofitable.

Growing Profit Margin: IVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.

Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: IVA has a negative Return on Equity (-55.85%), as it is currently unprofitable.


Financial Health

How is Inventiva's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IVA's short term assets (€115.6M) exceed its short term liabilities (€22.9M).

Long Term Liabilities: IVA's short term assets (€115.6M) exceed its long term liabilities (€10.3M).


Debt to Equity History and Analysis

Debt Level: IVA has more cash than its total debt.

Reducing Debt: IVA's debt to equity ratio has increased from 1.7% to 11.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IVA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IVA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 18.3% each year.


Dividend

What is Inventiva current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IVA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average management tenure


CEO

Frederic Cren (55 yo)

11.33yrs

Tenure

€928,791

Compensation

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...


CEO Compensation Analysis

Compensation vs Market: Frederic's total compensation ($USD992.51K) is above average for companies of similar size in the French market ($USD456.58K).

Compensation vs Earnings: Frederic's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IVA's management team is seasoned and experienced (9.8 years average tenure).


Board Members

Experienced Board: IVA's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Inventiva S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Inventiva S.A.
  • Ticker: IVA
  • Exchange: ENXTPA
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €360.787m
  • Shares outstanding: 40.86m
  • Website: https://www.inventivapharma.com

Number of Employees


Location

  • Inventiva S.A.
  • 50 rue de Dijon
  • Daix
  • Burgundy
  • 21121
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.